“…In the cobra venom factor (CVF) 1 model of lung injury, the CVF preparation must be able to activate not only C3 but also C5 (8), accordingly, hereditary absence of C5 protects the subject from lung injury (9). In vivo infusion of zymosan-activated plasma causes neutropenia (10,11), but little evidence of lung injury unless the activated plasma is repetitively infused (12). In experimental systems, interference with complement availability can be achieved either by complement blockade using recombinant soluble complement receptor-1 (sCR1) (13,14) or by the use of complement depletion procedures involving serial intraperitoneal injections of CVF (15,16).…”